Standalone CBN 5-15 mg pre-bed (typical starter dose):

• Onset 30-90 min (oral capsule/gummy); 15-30 min if sublingual tincture.
• Subjective effect: subtle. Most users describe mild body relaxation, slight heaviness in the limbs, occasional light head feel. Effects are notably weaker than melatonin at 0.5 mg or magnesium glycinate at 400 mg for sleep onset specifically.
• Sleep onset: small or negligible improvement vs no intervention; mixed reports.
• Sleep maintenance: occasional reports of fewer nighttime awakenings; not consistent across users.
• Morning effects: variable. About 20-30% of users report next-morning grogginess or a "fuzzy-head" feel lasting 1-3 hours after waking, consistent with the long half-life.
• Cumulative effects: with chronic nightly dosing for >4-6 days, plasma steady state is reached and morning carryover becomes more pronounced. Some users report this resolves with cycled dosing (3-4 nights on, 1-2 off) rather than nightly use.

Standalone CBN 20-25 mg pre-bed (upper end):

• More noticeable body relaxation and mild head feel, especially in cannabinoid-naive users.
• Slight increase in sleep onset signal, but also more reports of vivid dreams and morning grogginess.
• Some sensitive users describe a mild "stoned" feel at this dose — consistent with partial CB1 agonism amplifying near a perceptible threshold.

Stacked CBN + CBD (common commercial format, e.g., 10 mg CBN + 25 mg CBD):

• Generally better-rated than CBN alone in user reports — likely because CBD's anxiolytic and 5-HT1A activity contribute non-redundantly to the sleep effect.
• The "entourage" rationale is mechanistically partial — CBN and CBD work via different receptors — and clinically the combination produces more reliable sleep-quality reports than either alone in retrospective cohort data.

Stacked CBN + THC (common in legal-market sleep products):

• Acts much like a slightly-lower-dose THC product; the CBN contribution is small relative to THC's CB1 agonism.
• Drug-test risk is the same as any THC product.

• Tolerance: cannabinoid receptor downregulation has been documented for chronic high-dose THC use. CBN is a partial agonist with lower intrinsic efficacy, so the tolerance signal is weaker, but chronic nightly use likely produces some receptor downregulation over weeks. Most users do not report dramatic tolerance development at 5-25 mg pre-bed.
• Cycling: not strictly required. PRN use (occasional pre-bed nights, e.g., 2-4 nights/week) is reasonable and avoids steady-state accumulation.
• Discontinuation: no withdrawal syndrome at supplement doses. Brief sleep disruption (1-3 nights) on discontinuation has been reported anecdotally, similar to the rebound seen with any sleep aid.

Synergistic with

• CBD (15-30 mg pre-bed): non-redundant mechanisms (CBD's 5-HT1A agonism, GPR55 antagonism, and indirect GABA modulation complement CBN's weak partial CB1 agonism). The most common commercial format (CBN+CBD gummies) outperforms CBN alone in user reports.
• Low-dose melatonin (0.3-0.5 mg, 30-60 min before bed): different mechanism (MT1/MT2 signaling); safe co-admin; the user already has melatonin as a planned phase-shift tool, not a hypnotic — the combination would be redundant for his use case.
• Myrcene-rich terpene products: mechanistically synergistic (the actual "sedative cannabinoid + sedative terpene" entourage), though commercial standardization is poor.
• L-theanine (200 mg): different mechanism (AMPA/NMDA modulation, alpha-wave shift); safe co-admin for relaxation.
• Glycine (3 g pre-bed): different mechanism (thermoregulatory + NMDA glycine-site); safe co-admin. The user already has glycine in his V4 stack — would not add CBN on top.

Avoid stacking with

• Alcohol: additive CNS depression; impaired coordination; real risk.
• Benzodiazepines, Z-drugs (zolpidem, eszopiclone), barbiturates: additive sedation, respiratory depression risk especially in combination.
• Opioids: additive respiratory depression, dangerous combination at clinical doses.
• Other CB1 agonists (THC, synthetic cannabinoids like JWH-018, Spice): additive CB1 effects; the molecules don't combine usefully and increase psychoactive load.
• Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice): may elevate CBN plasma levels significantly; awareness rather than avoidance.
• Strong CYP3A4 inducers (rifampicin, carbamazepine, St. John's Wort): may reduce CBN exposure; awareness.

Neutral / safe co-administration

• All V4 stack items (DHA, citicoline, NAC, PS, curcumin, rhodiola, theanine, D3+K2, beta-alanine, vitamin C, glycine, magnesium glycinate, magtein, lion's mane, ashwagandha): no PK or PD conflicts.
• Modafinil, armodafinil: orthogonal mechanism + opposite timing (AM wake-promoter vs PM sedative); no conflict at correct dosing schedules.
• Caffeine: no interaction beyond timing — caffeine cutoff should be ≥10 hr pre-bed regardless.
• Creatine, beta-alanine, l-citrulline: no interaction.

CYP enzymes: CBN is a substrate and weak inhibitor of CYP2C9 and CYP3A4. Glucuronidated post-oxidation by UGT1A9 / UGT2B7. The CYP inhibition signal is weaker than CBD's at supplement doses but sufficient to flag in combination with narrow-therapeutic-index drugs.

Practical for the user: No current V4/V5 medications meaningfully interact with CBN at 5-25 mg doses. The drug-screen risk from contaminated product is the dominant practical concern given his MMA athletic context.

CYP2C9 polymorphisms (drives CBN oxidative metabolism):

• *CYP2C92 (rs1799853) / *3 (rs1057910)**: reduced-activity alleles; carriers have higher cannabinoid plasma exposure at standard doses. *3 homozygotes (~1% Caucasian) clear at roughly 30% of normal rate. Reported on 23andMe.
• For carriers of *2/*2, *2/*3, or *3/*3 — start at half the typical CBN dose (2.5-5 mg) and titrate slowly.

CYP3A4 / CYP3A5 polymorphisms (secondary CBN metabolism):

• CYP3A5*3 (rs776746): most non-Africans are *3/*3 (CYP3A5 non-expressers); CYP3A4 dominates. Limited practical implication for CBN.
• CYP3A4*22 (rs35599367): reduced-activity allele; ~5-10% Caucasian carrier frequency. May modestly increase CBN exposure.

FAAH (fatty acid amide hydrolase) C385A (rs324420):

• A allele carriers (~20% Caucasian) have reduced FAAH activity → higher endogenous anandamide tone. Subjectively report increased sensitivity to cannabinoids and to anxiety in some contexts. A/A homozygotes may be more responsive to low-dose CBN; would also be more sensitive to any CB1 agonism. Reported on 23andMe / Promethease.

CNR1 (cannabinoid receptor 1) gene variants:

• Several SNPs (rs1049353, rs806378, rs2023239) associated with cannabis-response variation, anxiety phenotypes, and addiction risk profiles. Practical interpretation for CBN supplementation: limited direct guidance, but A allele carriers at rs1049353 may be more sensitive to CB1-mediated effects.

Practical action for the user after 23andMe (June 2026): If the user ever did consider CBN despite the WATCH-LIST verdict, pull CYP2C9 *2/*3 and FAAH C385A status to inform dose. A/A FAAH or *3 carrier at CYP2C9 → start at 2.5-5 mg max. Otherwise standard 5-10 mg starter dose. No CPIC guideline for CBN dosing exists.

The contamination problem. Multiple 2022-2024 FDA warning letters and third-party lab surveys have documented widespread Δ9 and Δ8-THC contamination in commercial CBN products. Typical findings:

• 30-50% of online CBN products contain >0.3% Δ9-THC by weight (federally illegal hemp threshold).
• ~10-20% contain detectable Δ8-THC (not Schedule I federally but banned in some states; produces detectable urinary metabolite cross-reactive on standard drug screens).
• ~5-15% contain CBD as the dominant cannabinoid with little or no actual CBN despite labeling.
• Mislabeling errors of ±50% on stated CBN dose are common.

Practical sourcing for users in this archetype (US):

• Recommended: Do not use CBN. The user's V4/V5 stack already covers sleep with cleaner-evidenced and lower-risk alternatives (magnesium glycinate, magtein, glycine, planned l-tryptophan, planned apigenin, low-dose melatonin if needed). Adding CBN is redundant on the upside and adds drug-test contamination risk on the downside.
• If CBN were to be used despite the WATCH-LIST verdict: Charlotte's Web Sleep CBN gummies, Lazarus Naturals CBN tincture, or Slumber CBN tincture — all from vendors with public ISO/IEC 17025 COAs accessible by lot number. Verify the COA shows <0.1% Δ9 + Δ8 THC contamination before any use.
• For an MMA / drug-tested athlete: never use any CBN product without an athlete-grade COA from BSCG (Banned Substances Control Group), Informed Sport, or NSF Certified for Sport. The supplement-contamination risk for a tested athlete is real and career-impacting.

Estimated cost if used: ~$30-80/month for a typical 30-night supply; not cost-prohibitive but the cost-benefit ratio is unfavorable given the modest evidence and drug-test risk.

Baseline (before starting, if used)

• Sleep diary 14 days: sleep onset time, total sleep time, mid-sleep awakenings, morning alertness 1-10.
• Insomnia Severity Index (ISI) score — primary subjective sleep outcome.
• PSQI (Pittsburgh Sleep Quality Index) — secondary subjective sleep quality measure.
• Wearable sleep tracking (Colmi R06 ring data the user already has) — sleep timing, fragmentation, imperfect sleep stage.
• Liver enzymes (ALT/AST) — baseline if planning chronic use; very low concern at 5-25 mg pre-bed.
• Drug screen baseline (urinary Δ9-THC-COOH) — for tested athletes, document a clean baseline before any cannabinoid product use. Critical context for any future positive screen.

During use

• Sleep diary continuous — primary outcome.
• Morning alertness 1-10 — assess grogginess; primary side-effect tracking.
• Sleep architecture from wearable — assess WASO, total sleep time, sleep timing.
• Drug screen if tested — repeat at 2-4 weeks of use to detect contamination-driven positivity. Critical for any MMA / USADA / NCAA athlete.

Post-discontinuation

• Sleep diary for 1-2 weeks to assess rebound and confirm benefit was real (vs placebo + regression to mean).